We are live on ! Find out more
EYEGW

Eyegate Pharmaceuticals, Inc. Warrants
EYEGW

Delisted

EYEGW was delisted on the 5th of August, 2020.

Back to rankings

3 hedge funds and large institutions have $3K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 2 → 3 (+1)

67% less capital invested

Capital invested by funds: $9K → $3K (-$6K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$17

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.01K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIC
1
AWM Investment Company
New York
$3K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
– -$1.01K -32,179 -69%
UBS Group
3
UBS Group
Switzerland
– +$17 +545 New

EYEGW Hedge Fund Activity: Q1 2019 in Review

3 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q1 2019, worth a combined $3K — down 67% from $9K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new EYEGW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $17. The largest seller was Susquehanna International Group, cutting an estimated $1.01K.

  • 3 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q1 2019, up from 2 in Q4 2018.
  • Funds reported $3K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q1 2019, down 67% quarter-over-quarter.
  • 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q1 2019 and 0 closed out, a net change of +1 holder.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q1 2019 was UBS Group, an estimated $17 added.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q1 2019 was Susquehanna International Group, an estimated $1.01K sold.

Based on aggregated 13F filings for Q1 2019.